José Mesquita Bastos

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension

Susana Lopes, José Mesquita Bastos, Catarina Garcia et al. · JAMA Cardiology · 2021 · 122 citations · Full text

Medicine, Cardiology, Exercise Physiology +16

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Poly(1,20-eicosanediyl 2,5-furandicarboxylate), a biodegradable polyester from renewable resources

Maria J. Soares, Patrick‐Kurt Dannecker, Carla Vilela et al. · European Polymer Journal · 2017 · 54 citations

Natural Sciences, Biotechnology, Chemistry +16